Myriad Genetics (MYGN) PT Lowered to $4 at TD Cowen
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/27/2026
- Wall Street ends higher on revived AI momentum
- Meta's $97.5B AI money grab: why Zuckerberg is racing to raise cash before rivals
- Deutsche Bank’s Reid sees potential final dip this year before Santa rally
- UPS tops estimates as efficiency drive gains momentum
- GM to move stock listing to Nasdaq in November, shares gain
Tweet
Share
E-mailGet Alerts MYGN Hot Sheet
Price: $6.29 +4.49%
Rating Summary:
6 Buy, 20 Hold, 4 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 11 | Down: 18 | New: 18
Rating Summary:
6 Buy, 20 Hold, 4 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 11 | Down: 18 | New: 18
Join SI Premium – FREE
TD Cowen analyst Kyle Boucher lowered the price target on Myriad Genetics (NASDAQ: MYGN) to $4.00 (from $6.00) while maintaining a Hold rating.
You May Also Be Interested In
- Applied Industrial Technologies (AIT) PT Lowered to $360 at KeyBanc
- Royal Caribbean Cruises (RCL) PT Raised to $350 at Jefferies
- Ballard Power Systems (BLDP) PT Lowered to $1.68 at Jefferies
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
